Promises
2 promises
Promise Tracker
0 delivered, 0 close, 2 missed.
View Promises →
Aurobindo Pharma Limited — Q3 FY26
Aurobindo Pharma reported a strong quarter with PAT of INR 910 crore, supported by improving Pen G yields and a favorable government MIP policy on key antibiotics.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Aurobindo Pharma reported a strong quarter with PAT of INR 910 crore, supported by improving Pen G yields and a favorable government MIP policy on key antibiotics. The company is ramping Pen G production to over 10,000 metric tons annualized, with EBITDA breakeven already achieved. Europe continues double-digit growth, and the U.S. injectables business grew 17% despite the ongoing Eugia warning letter. Management guided for EBITDA margins in the 20-21% range for FY26 and expects meaningful contributions from Dayton and Raleigh facilities from FY27. Key risks include the timing of the Eugia warning letter resolution and potential delays in the Lannett acquisition.
ऑरोबिंदो फार्मा ने इस तिमाही में 910 करोड़ रुपये का शुद्ध लाभ कमाया। यह पेन G (एक दवा बनाने का कच्चा माल) की पैदावार बढ़ने और सरकार की न्यूनतम आयात मूल्य नीति से हुआ। कंपनी पेन G का उत्पादन सालाना 10,000 मीट्रिक टन से ऊपर ले जा रही है और इससे होने वाला खर्च निकालने के बाद भी मुनाफा हो रहा है। यूरोप में बिक्री दो अंकों की दर से बढ़ रही है, और अमेरिका में इंजेक्शन का कारोबार 17% बढ़ा, भले ही यूजिया पर चेतावनी पत्र लटका हो। कंपनी का अनुमान है कि अगले वित्त वर्ष में उसका मुनाफा (EBITDA) 20-21% रहेगा और डेटन व रैले कारखानों से FY27 से अच्छा योगदान मिलेगा। मुख्य जोखिम हैं: यूजिया चेतावनी पत्र का समाधान होने में देरी और लैनेट खरीद में रुकावट।
Promises0 met · 2 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Eugia warning letter resolution uncertainty
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Pen G annualized production
10,000 metric tons
+138% vs prior year average
Ramp-up progressing; yields improving consistently; expected to reach 65-70% capacity by March 2026.
U.S. injectable sales growth
17%
+17% YoY
Supported by supply ramp-up and improved service levels; injectable business showing steady improvement.
Europe constant currency growth
Low double-digit
Low double-digit YoY
Well ahead of market growth; driven by France, Portugal, Germany, Netherlands; China supply improving.
Pen G capacity utilization target
65-70%
+23-28pp vs 42% prior year average
Ramp-up on track; January 2026 already significantly ramped; MIP policy a positive catalyst.
What Changed vs Last Quarter
NEW
Pen G production to exceed 10,000 metric tons annualized in next 12 months
Based on current production levels, the company expects to produce more than 10,000 metric tons on an annualized basis over the next 12 months.
NEW
Dayton facility to contribute significantly from FY27
The Dayton facility has transitioned to commercial phase and will begin contributing revenues significantly from FY2027 onwards.
NEW
Lannett acquisition expected to close in Q1 FY27
The acquisition is progressing well with FTC; expected to close in the first quarter of FY2027.
UPDATED
EBITDA margin target of 20-21% for FY26
Management expects to achieve EBITDA margins on the higher side of 20-21% for FY2026, driven by Pen G ramp-up, injectable growth, and cost efficiencies.
DROPPED
Europe to exceed EUR 1 billion annual revenue by FY26 end
European business on track to comfortably surpass EUR 1 billion annual revenue milestone by end of FY26, driven by consistent growth across major markets.
DROPPED
China OSG facility EBITDA breakeven by Q3-Q4 FY26
The OSG facility in China is on track to deliver EBITDA breakeven by Q3-Q4 FY26, with European approval for 10 products and 3 local approvals.
DROPPED
Biosimilar denosumab EU submission in April 2026
Marketing authorization application for denosumab biosimilar to be submitted to EMA in April 2026; FDA submission expected in July quarter of 2026.
NEW RISK
Eugia warning letter resolution uncertainty
Despite procedural observations, the USFDA decision on the warning letter is pending; management is cautiously optimistic but cannot predict outcome.
NEW RISK
6-APA predatory pricing impact
6-APA prices have been below cost of manufacture internationally, causing losses; correction expected by April but timing uncertain.
NEW RISK
Lannett acquisition regulatory delays
FTC approval process is ongoing; any delay or unexpected conditions could impact the timeline and synergies.
NEW RISK
Ramp-up costs from multiple greenfield projects
EBITDA burn from ramping up facilities like Pen G, Dayton, Raleigh, and biosimilars may pressure near-term margins.
RISK GONE
UGF3 reinspection delay
FDA reinspection for UGF3 facility is pending; timeline is uncertain (up to 8 months from September 2025), delaying injectable product launches.
RISK GONE
Pen-G MIP policy uncertainty
Minimum import price (MIP) representation to government is pending; if delayed or denied, Pen-G ramp-up and profitability may be impacted.
RISK GONE
Biosimilar competitive intensity
New FDA draft guidance may lower entry barriers, increasing competition; Aurobindo may be third or later entrant in key products like denosumab.
RISK GONE
High CapEx intensity
H1 CapEx at INR 1,500 crore; ongoing investments in biosimilars, biologics CMO, and Pen-G may pressure cash flows despite unutilized capacities.
🤫 Topics management stopped discussing
Mentioned in Q1 FY25, Q2 FY25, Q3 FY25
Omalizumab and ophthalmic product trials are delayed; ophthalmic recruitment only 50% and expected to complete in H2 2026, pushing back potential launches.
Mentioned in Q1 FY26, Q2 FY26
The OSG facility in China is on track to deliver EBITDA breakeven by Q3-Q4 FY26, with European approval for 10 products and 3 local approvals.
Mentioned in Q1 FY25, Q3 FY25
The China OSD plant (2B units capacity) commercialized in November 2024, expected to ramp up and contribute to revenues in FY26, initially supplying Europe.
Mentioned in Q3 FY25, Q4 FY25
The US-based OSD plant at Dayton is expected to commence commercial manufacturing in Q2 of FY26.
Fast read
Guidance and risk preview
Management expects to achieve EBITDA margins on the higher side of 20-21% for FY2026, driven by Pen G ramp-up, injectable growth, and cost efficien...
Despite procedural observations, the USFDA decision on the warning letter is pending; management is cautiously optimistic but cannot predict outcome.
View Risks →